Table 3.
Parameters for estimation of ADR incidence from both active and passive surveillance, January 2004 to December 2005
| |
RUFIJI District |
|
|---|---|---|
| KILOMBERO/ ULANGA Districts | ||
|
Probable ADR events detected by passive surveillance: | ||
| SP monotherapy |
7 |
13 |
| Artesunate monotherapy |
0 |
0 |
| Combination of AS/SP |
3 |
0 |
| Total |
10 |
13 |
|
Probable ADR events detected by active surveillance: | ||
| SP monotherapy |
2 |
7 |
| Artesunate monotherapy |
0 |
0 |
| Combination of AS/SP |
2 |
0 |
| Total |
4 |
7 |
|
Total probable ADR events detected: | ||
| SP monotherapy |
9 |
20 |
| Artesunate monotherapy |
0 |
0 |
| Combination of AS/SP |
5 |
0 |
| Total |
14 |
20 |
|
Total Population Under DSS Surveillance |
84,500 |
74,200 |
|
Estimates of average annual anti-malarial drug exposure rates in the DSS areas per capita: | ||
| SP monotherapy |
0.46 |
0.54 |
| Artesnuate monotherapy |
0.37 |
0 |
| Combination of AS/SP |
0.53 |
0 |
|
Estimate of total doses used by the DSS population in 2004/5 (population * average annual exposure) | ||
| SP monotherapy |
38,870 |
40,068 |
| AS monotherapy |
31,265 |
0 |
| Combination of AS/SP |
44,785 |
0 |
|
Estimated ADR incidence per 100,000 exposures1 | ||
| SP monotherapy |
11.6 |
25.0 |
| AS monotherapy |
0 |
- |
| Combination of AS/SP | 5.6 | - |
1Calculated as (Number of “probable” ADR cases / estimated total doses used) * 0.5 (multiplied by 0.5 to annualize ADR occurrence rates since our data cover a two year period).